

II. RESPONSE

A. Status of the Claims

Claims 14-30 were pending at the time of the Restriction Requirement, with claims 1-13 having been previously canceled in the Preliminary Amendment filed with the application. Claims 14-24 are canceled herein in view of the election of the Group II invention below. Claims 31-35 have been added by amendment. Support for the new claims is found in the specification and claims as originally filed. No new matter is added by this amendment.

In view of the above, claims 25-35 are pending after entry of the amendment.

B. Response to Restriction Requirement

In response to the restriction requirement, Applicants elect, *without traverse*, to prosecute the Group II invention in the present application, as exemplified by current claims 25-35, drawn to a method comprising obtaining an agent prepared from plant seedlings enriched with electrolytes comprised in a pharmaceutical preparation and administering the preparation to a person, wherein administration of the preparation results in reduction of blood cholesterol concentration in the person.

C. Species Election

In response to the species election requirement entered by the Examiner for the Group II invention, Applicants elect, *without traverse*, as the result of administration, the reduced probability of atherosclerosis according to claim 27. Current claims 25-35 are generic to this species. In this regard, Applicants point out that specific results of the practice of the method of claim 25 in claims 26-28 and 31-35, are not exclusive. Therefore, it is possible that, for example, the practice of the method of claim 25 can result in both a reduced probability of atherosclerosis and in proliferation of T-lymphocytes, for example, CD3-/CD16,56+-specific immune cells. Therefore, all of these claims are generic with regard to the elected species.


Applicants reserve the right to have any and all dependent claims directed to the non-elected species examined in the present case if any of the above-mentioned generic claims or any other generic claims encompassing such non-elected species within their scope are found to be allowable.

D. Conclusion

Applicants believe that they have submitted a complete reply to the Restriction Requirement dated September 15, 2006, and respectfully request favorable consideration of the claims in view of the amendments and statements contained herein.

Should the Examiner have any questions, comments, or suggestions relating to this case, the Examiner is invited to contact the undersigned Applicants' representative at (512) 536-3035.

Respectfully submitted,



Mark B. Wilson

Reg. No. 37,259

Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
512.536.3035 (voice)
512.536.4598 (fax)

Date: October 16, 2006